VSAR Market Cap History
Below is a table of the VSAR market cap history going back to 4/30/2014:

Date VSAR Market Cap
4/30/2014738.43M
7/31/2014493.57M
10/31/2014481.72M
2/28/2015579.55M
4/30/2015499.87M
7/31/2015531.27M
10/31/2015303.29M
2/29/2016193.30M
4/29/2016266.63M
7/29/2016339.72M
11/2/2016344.48M
2/28/2017765.76M
4/30/2017647.85M
7/31/2017658.20M
10/31/201764.46M
2/28/201857.69M
4/9/201856.81M
4/30/201854.12M
7/31/201861.61M

Also see: VSAR Shares Outstanding History
and VSAR YTD Return
VSAR Historical Market Cap:
-44.22% CAGR
VSAR Historical Market Cap: +-44.22% CAGR

Mouse over chart for data details
4/30/2014 ...7/31/2018
Aravive is an endocrine-focused biopharmaceutical company that engaged in developing a long-acting form of recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease that affects pediatric and adult patients. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN™. Somavaratan includes a long N-terminal XTEN sequence, XTEN1, which is added to rhGH as a fusion protein, increasing the hydrodynamic size of the rhGH and thereby reducing glomerular filtration. A C-terminal XTEN sequence, XTEN2, is also added to reduce receptor mediated clearance by decreasing receptor binding. We show 19 historical shares outstanding datapoints in our VSAR shares outstanding history coverage, used to compute VSAR market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing VSAR market cap history over the course of time is important for investors interested in comparing VSAR's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of VSAR versus a peer is one thing; comparing VSAR market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like VSAR can fluctuate over the course of history. With this page we aim to empower investors researching VSAR by allowing them to research the VSAR market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree VSAR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Versartis (VSAR) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

VSTM Market Cap History
VTGN Market Cap History
VTL Market Cap History
VTRS Market Cap History
VTVT Market Cap History
VVOS Market Cap History
VVUS Market Cap History
VXRT Market Cap History
VYGR Market Cap History
VYNE Market Cap History
More Healthcare companies »

 

VSAR Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.